BREAKINGVIEWS-Novo Nordisk is Denmark’s big little problem: podcast

Eli Lilly and Company -1.98%

Eli Lilly and Company

LLY

935.58

-1.98%

The hosts are Reuters Breakingviews columnists. The opinions expressed are their own.

By Aimee Donnellan and Jonathan Guilford

LONDON/NEW YORK, March 26 (Reuters Breakingviews) - Follow on Apple or Spotify. Listen on the Reuters app. Read the episode transcript.

Listen to the podcast

As war rages and Donald Trump looms, a recent election featured little mention of the ailing $164 bln drugmaker, once so successful it distorted economic figures. In this week’s Viewsroom, Breakingviews columnists discuss the future of weight loss pills, and Novo’s place in it.

Follow Aimee Donnellan on LinkedIn.

Follow Jonathan Guilford on X and LinkedIn.

FURTHER READING

Novo Nordisk's illness offers painful lessons

Novo Nordisk’s falling knife is still gathering speed

Obesity pills are shaky Hail Mary for Novo Nordisk

Visit the Thomson Reuters Privacy Statement for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices to opt-out of targeted advertising.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.